Fertility and reproductive considerations in premenopausal patients with breast cancer

Cancer Control

Volumn 17, Issue 3, 2010, Pages 162-172

  Catherine Lee, M ^a   Gray, Jhanelle ^a   Han, Hyo Sook ^a   Plosker, Shayne ^b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; GONADORELIN AGONIST; GONADORELIN DERIVATIVE; GONADOTROPIN DERIVATIVE; GOSERELIN; LETROZOLE; METHOTREXATE; PACLITAXEL; TAMOXIFEN; TRIPTORELIN;

ADJUVANT THERAPY; AMENORRHEA; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CRYOPRESERVATION; FEMALE; FEMALE FERTILITY; FEMALE GENITAL SYSTEM; FERTILIZATION IN VITRO; HUMAN; INFERTILITY THERAPY; MONOTHERAPY; OVULATION INDUCTION; PATIENT COUNSELING; PREGNANCY RATE; PREMENOPAUSE; SURVIVAL RATE; TERATOGENICITY;

EID: 77954997497     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327481001700304     Document Type: Article

References (68)

1. American Cancer Society. Cancer Facts & Figures 2009. Atlanta, GA: American Cancer Society, Inc; 2009. http://www.cancer.org/down-loads/STT/ 500809web.pdf. Accessed May 24, 2010.
2. American Cancer Society. Breast Cancer Facts & Figures 2007-2008. Atlanta, GA: American Cancer Society, Inc; 2008. http://www.cancer.org/ downloads/stt/bcff-final.pdf. Accessed April 10, 2010.
3. Reh A, Oktem O, Oktay K. Impact of breast cancer chemotherapy on ovarian reserve: a prospective observational analysis by menstrual history and ovarian reserve markers. Fertil Steril. 2008;90(5):1635-1639.
4. Badawy A, Elnashar A, El-Ashry M, et al. Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. Fertil Steril. 2009;91(3):694-697.
5. Anderson RA, Themmen AP, Al-Qahtani A, et al. The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer. Hum Reprod. 2006; 21(10):2583-2592.
6. Bianco AR, Del Mastro L, Gallo C, et al. Prognostic role of amenor-rhea induced by adjuvant chemotherapy in premenopausal patients with early breast cancer. Br J Cancer. 1991;63(5):799-803.
7. Bines J, Oleske DM, Cobleigh MA. Ovarian function in pre-menopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol. 1996;14(5):1718-29.
8. Goldhirsch A, Gelber RD, Castiglione M. The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients. The International Breast Cancer Study Group. Ann Oncol. 1990;1(3):183-188.
9. Dnistrian AM, Schwartz MK, Fracchia AA, et al. Endocrine consequences of CMF adjuvant therapy in premenopausal and postmenopausal breast cancer patients. Cancer. 1983;51(5):803-807.
10. American Congress of Obstetricians and Gynecologists. www.acog. org. Accessed April 10, 2010.
11. Valagussa P, Moliterni A, Zambetti M, et al. Long-term sequelae from adjuvant chemotherapy. Recent Results Cancer Res. 1993;127:247-255.
12. Davis VJ. Female gamete preservation. Cancer. 2006;107(7 suppl):1690-1694.
13. Gadducci A, Cosio S, Genazzani AR. Ovarian function and child-bearing issues in breast cancer survivors. Gynecol Endocrinol. 2007;23(11): 625-631.
14. Minton SE, Munster PN. Chemotherapy-induced amenorrhea and fertility in women undergoing adjuvant treatment for breast cancer. Cancer Control. 2002;9(6):466-472.
15. Fornier MN, Modi S, Panageas KS, et al. Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane. Cancer. 2005; 104(8):1575-1579.
16. Tham YL, Sexton K, Weiss H, et al. The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane. Am J Clin Oncol. 2007;30(2):126-132.
17. Swain SM, Land SR, Ritter MW, et al. Amenorrhea in premeno -pausal women on the doxorubicin-and-cyclophosphamide-followed-by-doc-etaxel arm of NSABP B-30 trial. Breast Cancer Res Treat. 2009;113(2): 315-320.
18. Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005;352(22):2302-2313.
19. Lee SJ, Schover LR, Partridge AH, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol. 2006;24(18):2917-2931.
20. Goldhirsch A, Ingle JN, Gelber RD, et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer. 2009. Ann Oncol. 2009;20(8):1319-1329.
21. Goodwin PJ, Ennis M, Pritchard KI, et al. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol. 1999;17(8):2365-2370.
22. Barthelmes L, Gateley CA. Tamoxifen and pregnancy. Breast. 2004; 13(6):446-451.
23. Fox KR, Scialla J, Moore H. Preventing chemotherapy-related amonorrhea using leuprolide during adjuvant chemotherapy for early-stage breast cancer. Proc Am Soc Clin Oncol. 2003;22(13). Abstract 50.
24. Del Mastro L, Catzeddu T, Boni L, et al. Prevention of chemotherapy-induced menopause by temporary ovarian suppression with goserelin in young, early breast cancer patients. Ann Oncol. 2006;17(1):74-78.
25. Recchia F, Saggio G, Amiconi G, et al. Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma. Cancer. 2006;106(3):514-523.
26. Urruticoechea A, Arnedos M, Walsh G, et al. Ovarian protection with goserelin during adjuvant chemotherapy for pre-menopausal women with early breast cancer (EBC). Breast Cancer Res Treat. 2008;110(3):411-416.
27. Ismail-Khan R, Minton S, Cox C, et al. Preservation of ovarian function in young women treated with neoadjuvant chemotherapy for breast cancer: a randomized trial using the GnRH agonist (triptorelin) during chemotherapy J Clin Oncol ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2008;26:15S. Abstract 524.
28. Gerber B, Stehle H, Ricardo F, et al. ZORO: a prospective randomized multicenter study to prevent chemotherapy-induced ovarian failure with the GnRH-agonist goserelin in young hormone-insensitive breast cancer patients receiving anthracycline containing (neo-) adjuvant chemotherapy (GBG 37). J Clin Oncol. 2009;27(15s). Abstract 526.
29. 2006 Assisted Reproductive Technology (ART) Report. Centers for Disease Control and Prevention. http://www.cdc.gov/ART/ART2006. Accessed May 6, 2010.
30. Ovarian tissue and oocyte cryopreservation. Practice Committee of the American Society for Reproductive Medicine and Practice Committee of the Society for Assisted Reproductive Technology. Fertil Steril. 2008;90(5 suppl):S241-S246.
31. Boldt J, Tidswell N, Sayers A, et al. Human oocyte cryopreservation: 5-year experience with a sodium-depleted slow freezing method. Reprod Biomed Online. 2006;13(1):96-100.
32. Grifo JA, Noyes N. Delivery rate using cryopreserved oocytes is comparable to conventional in vitro fertilization using fresh oocytes: potential fertility preservation for female cancer patients. Fertil Steril. 2009;93(2):391-396.
33. Demeestere I, Simon P, Emiliani S, et al. Orthotopic and heterotopic ovarian tissue transplantation. Hum Reprod Update. 2009;15(6):649-665.
34. Fabbri R, Pasquinelli G, Keane D, et al. Culture of cryopreserved ovarian tissue: state of the art in 2008. Fertil Steril. 2009;91(5):1619-1629.
35. Venn A, Watson L, Bruinsma F, et al. Risk of cancer after use of fertility drugs with in-vitro fertilisation. Lancet. 1999;354(9190):1586-1590.
36. Jensen A, Sharif H, Svare EI, et al. Risk of breast cancer after exposure to fertility drugs: results from a large Danish cohort study. Cancer Epidemiol Biomarkers Prev. 2007;16(7):1400-1407.
37. Oktay K, Hourvitz A, Sahin G, et al. Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy. J Clin Endocrinol Metab. 2006;91(10):3885-3890.
38. Steiner AZ, Terplan M, Paulson RJ. Comparison of tamoxifen and clomiphene citrate for ovulation induction: a meta-analysis. Hum Reprod. 2005;20(6):1511-1515.
39. Oktay K, Buyuk E, Libertella N, et al. Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J Clin Oncol. 2005;23(19):4347-4353.
40. Menon U, Harper J, Sharma A, et al. Views of BRCA gene mutation carriers on preimplantation genetic diagnosis as a reproductive option for hereditary breast and ovarian cancer. Hum Reprod. 2007;22(6):1573-1577.
41. Poniatowski BC, Grimm P, Cohen G. Chemotherapy-induced menopause: a literature review. Cancer Invest. 2001;19(6):641-648.
42. Partridge AH, Gelber S, Peppercorn J, et al. Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol. 2004;22 (20):4174-4183.
43. Thewes B, Meiser B, Rickard J, et al. The fertility- and menopause-related information needs of younger women with a diagnosis of breast cancer: a qualitative study. Psychooncology. 2003;12(5):500-511.
44. Thewes B, Butow P, Girgis A, et al. The psychosocial needs of breast cancer survivors; a qualitative study of the shared and unique needs of younger versus older survivors. Psychooncology. 2004;13(3):177-189.
45. Thewes B, Meiser B, Taylor A, et al. Fertility- and menopause-related information needs of younger women with a diagnosis of early breast cancer. J Clin Oncol. 2005;23(22):5155-5165.
46. Schover LR. Premature ovarian failure and its consequences: vasomotor symptoms, sexuality, and fertility. J Clin Oncol. 2008;26(5):753-758.
47. Quinn GP, Vadaparampil ST, Bell-Ellison BA, et al. Patient-physician communication barriers regarding fertility preservation among newly diagnosed cancer patients. Soc Sci Med. 2007;66(3):784-789.
48. Quinn GP, Vadaparampil ST, Gwede CK, et al. Discussion of fertility preservation with newly diagnosed cancer patients: oncologists' views. J Cancer Surviv. 2007;1(2):146-155.
49. Canada AL, Schover LR. Research promoting better patient education on reproductive health after cancer. J Natl Cancer Inst Monogr. 2005; (34):98-100.
50. Patel A, Sreedevi M, Malapati R, et al. Reproductive health assessment for women with cancer: a pilot study. Am J Obstet Gynecol. 2009;201(2):191. e1-e4.
51. Schover LR, Rybicki LA, Martin BA, et al. Having children after cancer: a pilot study of survivors' attitudes and experiences. Cancer. 1999 86(4): 697-709.
52. Tschudin S, Bitzer J. Psychological aspects of fertility preservation in men and women affected by cancer and other life-threatening diseases. Hum Reprod Update. 2009;15(5):587-597.
53. Partridge AH. Fertility preservation: a vital survivorship issue for young women with breast cancer. J Clin Oncol. 2008;26(16):2612-2613.
54. Connell S, Patterson C, Newman B. A qualitative analysis of reproductive issues raised by young Australian women with breast cancer. Health Care Women Int. 2006;27(1):94-110.
55. King L, Quinn GP, Vadaparampil ST, et al. Oncology social workers' perceptions of barriers to discussing fertility preservation with cancer patients. Soc Work Health Care. 2008;47(4):479-501.
56. King L, Quinn GP, Vadaparampil ST, et al. Oncology nurses' perceptions of barriers to discussion of fertility preservation with patients with cancer. Clin J Oncol Nurs. 2008;12(3):467-476.
57. Azim AA, Costantini-Ferrando M, Oktay K. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. J Clin Oncol. 2008; 26(16):2630-2635.
58. Madrigrano A, Westphal L, Wapnir I. Egg retrieval with cryopreser-vation does not delay breast cancer treatment. Am J Surg. 2007;194(4): 477-481.
59. Lohrisch C, Paltiel C, Gelmon K, et al. Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol. 2006;24(30):4888-4894.
60. Oktay K, Buyuk E, Davis O, et al. Fertility preservation in breast cancer patients: IVF and embryo cryopreservation after ovarian stimulation with tamoxifen. Hum Reprod. 2003;18(1):90-95.
61. Shetty G, Krishnamurthy H, Krishnamurthy HN, et al. Effect of estrogen deprivation on the reproductive physiology of male and female primates. J Steroid Biochem Mol Biol. 1997;61(3-6):157-166.
62. Mitwally MF, Casper RF. Aromatase inhibitors in ovulation induction. Semin Reprod Med. 2004;22(1):61-78.
63. Blakely LJ, Buzdar AU, Lozada JA, et al. Effects of pregnancy after treatment for breast carcinoma on survival and risk of recurrence. Cancer. 2004;100(3):465-469.
64. Ives A, Saunders C, Bulsara M, et al. Pregnancy after breast cancer: population based study. BMJ. 2007;334(7586):194.
65. Mueller BA, Simon MS, Deapen D, et al. Childbearing and survival after breast carcinoma in young women. Cancer. 2003;98(6):1131-1140.
66. Kroman N, Jensen MB, Melbye M, et al. Should women be advised against pregnancy after breast-cancer treatment? Lancet. 1997;350(9074): 319-322.
67. Sankila R, Heinavaara S, Hakulinen T. Survival of breast cancer patients after subsequent term pregnancy: healthy mother effect. Am J Obstet Gynecol. 1994;170(3):818-823.
68. Largillier R, Savignoni A, Gligorov J, et al. Prognostic role of pregnancy occurring before or after treatment of early breast cancer patients aged <35 years: a GET(N)A Working Group analysis. Cancer. 2009;115 (22):5155-5165.